Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery

References

• Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech 2005; 6: E144–9
   PubMedGoogle Scholar
• Csóka I, Csányi E, Zapantis G, Nagy E, Fehér-Kiss A, Horváth G, et al. In vitro and in vivo percutaneous absorption of topical dosage forms: Case studies. Int J Pharm 2005; 291: 11–9
   PubMed Web of Science ®Google Scholar
• Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Contr Rel 1994; 30: 1–15
   Web of Science ®Google Scholar
• Uchegbu IF, Schatzlein AG, Tetley L, Gray AI, Sludden J, Siddique S, et al. Polymeric chitosan-based vesicles for drug delivery. J Pharm Pharmacol 1998; 50: 453–8
   PubMed Web of Science ®Google Scholar
• Niven RW, Carvajal MA, Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res 1992; 9: 515–20
   PubMed Web of Science ®Google Scholar
• Wong M, Thompson T. Aggregation of dipalmitoylphosphotidylcholine vesicles. Biochemistry 1982; 21: 4133–9
   PubMed Web of Science ®Google Scholar
• Baillie A, Florence A, Hume L, Muirhead G, Rogerson A. Preparation and properties of niosomes-nonionic surfactant vesicles. J Pharm Pharmacol 1985; 37: 863–8
   PubMed Web of Science ®Google Scholar
• Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. Design and development of a proniosomal transdermal drug delivery system for captopril. Trop J Pharm Res 2007a; 6: 687–93
   Web of Science ®Google Scholar
• Hu C, Rhodes D. Proniosomes: A novel drug carrier preparation. Int J Pharm 1999; 185: 23–35
   PubMed Web of Science ®Google Scholar
• Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS Pharm Sci Tech 2007; 8(article 86)E1–7
   PubMedGoogle Scholar
• Florence AT. New drug delivery systems. Chem Ind 1993; 93: 1000–4
   Google Scholar
• Uchegbu IF, Vyas SP. Nonionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33–70
   Web of Science ®Google Scholar
• Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Contr Rel 1998; 54: 149–65
   PubMed Web of Science ®Google Scholar
• Gupta A, Prajapati SK, Singh M, Balamurugan M. Proniosomes powder of captopril: Formulation and evaluation. Molec Pharm 2007b; 4: 596–9
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J Pharm Sci 2002; 5: 220–5
   Web of Science ®Google Scholar
• Gude RP, Jadhav MG, Rao SG, Jagtab AG. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm 2002; 17: 183–92
   PubMed Web of Science ®Google Scholar
• Paolino D, Muzzalupo R, Ricciardi A, Celia C, Picci N, Fresta M. In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices 2007; 9: 421–33
   PubMed Web of Science ®Google Scholar
• Blazek-Welsh A, Rhodes DG. Maltodextrin based proniosomes. AAPS PharmSci 2001; 3: 1–8
   PubMed Web of Science ®Google Scholar
• Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2007; 18: 209–19
   Google Scholar
• Dalmora MEA, Oliveria AG. Inclusion complex of piroxicam with β-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int J Pharm 1999; 184: 157–64
   PubMed Web of Science ®Google Scholar
• Tagliati CA, Kimura E, Nothenberg MS, Santos SRJC, Oga S. Pharmacokinetics profile and adverse gastric effect of zinx-piroxicam in rats. Gen Pharmacol 1999; 13: 67–71
   Google Scholar
• Shin SC, Cho CW, Choi HK. Permeation of piroxicam from the poloxamer gels. Drug Dev Ind Pharm 1999; 25: 273–8
   PubMed Web of Science ®Google Scholar
• Chien YW. Logics of transdermal controlled drug administration. Drug Dev Ind Pharm 1983; 9: 497–520
   Web of Science ®Google Scholar
• Chien YW, Valia KH. Development of a dynamic skin permeation system for long-term permeation studies. Drug Dev Ind Pharm 1984; 10: 575–99
   Web of Science ®Google Scholar
• Murthy SN, Zhao YL, Sen A, Hui SW. Enhanced transdermal delivery of piroxicam and carboxyflurorescein by electroporation. J Contr Rel 2004; 99: 393–402
   PubMed Web of Science ®Google Scholar
• Curdy C, Kalia YN, Naik A, Guy RH. Piroxicam delivery into human stratum corneum in vivo: Iontophoresis versus passive diffusion. J Contr Rel 2001; 76: 73–9
   PubMed Web of Science ®Google Scholar
• Shin SC, Cho CW, Oh IJ. Enhanced efficacy by precutaneous absorption of piroxicam from the poloxamer gel in rats. Int J Pharm 2000; 193: 213–8
   PubMed Web of Science ®Google Scholar
• Canto GS, Dalmora SL, Oliveira AG. Piroxicam encapsulated in liposomes: Characterization and in vivo evaluation of topical anti-inflammatory effect. Drug Dev Ind Pharm 1999; 25: 1235–9
   PubMed Web of Science ®Google Scholar
• Jia-You F, Song-Yih Y, Pao-Chu W, Yaw-Bin H, Yi-Hung T. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001; 215: 91–9
   PubMedGoogle Scholar
• Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: In vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Contr Rel 2005; 106: 99–110
   PubMed Web of Science ®Google Scholar
• Doliwa A, Santoyo S, Campanero MA, Ygartua P. Sensitive LC determination of piroxicam after in vitro transdermal permeation studies. J Pharm Biomed Anal 2001; 26: 531–7
   PubMed Web of Science ®Google Scholar
• Ishii F, Takemura A, Ishigami Y. Procedures for preparation of lipid vesicles (liposomes) using coacervation (phase separation) technique. Langmuir 1995; 11: 483–6
   Web of Science ®Google Scholar
• Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005; 59: 485–90
   PubMed Web of Science ®Google Scholar
• Gulati M, Grover M, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 1998; 165: 129–68
   Web of Science ®Google Scholar
• Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60, and 80) and a sorbitan triester (Span 85). Int J Pharm 1994; 105: 1–6
   Web of Science ®Google Scholar
• Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228: 43–52
   PubMed Web of Science ®Google Scholar
• Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101–14
   PubMed Web of Science ®Google Scholar
• Fang J, Yu S, Wu P, Huang Y, Tsai Y. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001; 215: 91–9
   PubMed Web of Science ®Google Scholar
• Ogiso T, Niinaka N, Iwaki M. Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci 1996; 85: 57–64
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. Niosomal delivery of 5-fluorouracil. J Microencapsul. 1999; 16: 731–40
   PubMed Web of Science ®Google Scholar